Insulet (NASDAQ:PODD) Stock Price Expected to Rise, Sanford C. Bernstein Analyst Says

Insulet (NASDAQ:PODD) had its price objective increased by investment analysts at Sanford C. Bernstein from $175.00 to $200.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the medical instruments supplier’s stock. Sanford C. Bernstein‘s price objective would indicate a potential upside of 36.51% from the stock’s previous close.

Several other research analysts also recently commented on the company. Stifel Nicolaus reduced their price target on Insulet from $225.00 to $180.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Citigroup increased their price target on Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Oppenheimer lowered Insulet from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Jefferies Financial Group restated a “buy” rating and set a $200.00 price target on shares of Insulet in a report on Wednesday. Finally, BTIG Research downgraded shares of Insulet from a “buy” rating to a “neutral” rating in a research report on Thursday, August 6th. Twelve analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Insulet presently has a consensus rating of “Hold” and a consensus price target of $185.38.

Insulet Trading Down 6.2%

Shares of NASDAQ:PODD traded down $9.61 during mid-day trading on Thursday, reaching $146.51. 1,567,721 shares of the company’s stock were exchanged, compared to its average volume of 1,380,594. The firm has a market capitalization of $10.16 billion, a price-to-earnings ratio of 23.86, a PEG ratio of 1.21 and a beta of 1.06. The business’s fifty day moving average price is $141.97 and its 200-day moving average price is $176.65. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. Insulet has a twelve month low of $126.40 and a twelve month high of $354.88.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share for the quarter, topping the consensus estimate of $1.59 by $0.40. The company had revenue of $842.00 million for the quarter, compared to analysts’ expectations of $832.63 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. Insulet’s revenue for the quarter was up 19.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.24 earnings per share. On average, research analysts predict that Insulet will post 6.75 EPS for the current fiscal year.

Institutional Investors Weigh In On Insulet

Hedge funds have recently added to or reduced their stakes in the business. Diversified Trust Co lifted its stake in Insulet by 47.0% in the third quarter. Diversified Trust Co now owns 5,036 shares of the medical instruments supplier’s stock valued at $657,000 after buying an additional 1,611 shares during the period. Allworth Financial LP boosted its holdings in shares of Insulet by 2.3% during the 3rd quarter. Allworth Financial LP now owns 3,104 shares of the medical instruments supplier’s stock worth $405,000 after buying an additional 71 shares in the last quarter. Fifth Third Bancorp grew its position in shares of Insulet by 21.3% during the 3rd quarter. Fifth Third Bancorp now owns 64,540 shares of the medical instruments supplier’s stock worth $8,421,000 after buying an additional 11,334 shares during the period. Maryland State Retirement & Pension System grew its position in shares of Insulet by 22.5% during the 3rd quarter. Maryland State Retirement & Pension System now owns 4,176 shares of the medical instruments supplier’s stock worth $545,000 after buying an additional 768 shares during the period. Finally, Ritholtz Wealth Management acquired a new stake in shares of Insulet during the 3rd quarter worth approximately $276,000.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Several firms raised targets and maintained bullish ratings: RBC lifted its target to $180 and kept an Outperform rating, Bernstein raised its target to $200 and kept Outperform, and Canaccord reiterated Buy with a $179 target. RBC target update Canaccord rating update
• Positive Sentiment: Other analysts also raised targets, while commentary described Insulet as potentially undervalued and highlighted its $1 billion buyback. Recent quarterly results provide support: the company beat earnings and revenue estimates, with revenue up 19.2% year over year, according to the supplied company data. Valuation and buyback article
• Neutral Sentiment: UBS, JPMorgan, Citi, Barclays, Wells Fargo and Leerink all increased their price targets, generally retaining Neutral, Equal Weight or Market Perform ratings. The higher targets are supportive, but the largely unchanged ratings suggest analysts see risks as well as recovery potential.
• Negative Sentiment: Analyst discussion flagged a more conservative 2027 outlook and competition, tempering optimism about Insulet’s growth. Coverage characterized the outlook as moderate despite international strength and an innovation pipeline. RBC outlook article Q3 growth analysis

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.